Oseltamivir prophylaxis reduces inflammation and facilitates establishment of cross-strain protective T cell memory to influenza viruses

NL Bird; MR Olson; AC Hurt; CM Oshansky; DY Oh; PC Reading; BY Chua; Y Sun; L Tang; A Handel; DC Jackson; SJ Turner; PG Thomas; K Kedzierska

Journal article

Oseltamivir prophylaxis reduces inflammation and facilitates establishment of cross-strain protective T cell memory to influenza viruses

NL Bird, MR Olson, AC Hurt, CM Oshansky, DY Oh, PC Reading, BY Chua, Y Sun, L Tang, A Handel, DC Jackson, SJ Turner, PG Thomas, K Kedzierska

Plos One | Published : 2015

DOI: 10.1371/journal.pone.0129768

Download PDF

Abstract

CD8+ T cells directed against conserved viral regions elicit broad immunity against distinct influenza viruses, promote rapid virus elimination and enhanced host recovery. The influenza neuraminidase inhibitor, oseltamivir, is prescribed for therapy and prophylaxis, although it remains unclear how the drug impacts disease severity and establishment of effector and memory CD8+ T cell immunity. We dissected the effects of oseltamivir on viral replication, inflammation, acute CD8+ T cell responses and the establishment of immunological CD8+ T cell memory. In mice, ferrets and humans, the effect of osteltamivir on viral titre was relatively modest. However, prophylactic oseltamivir treatment in ..

View full abstract

University of Melbourne Researchers

Patrick Reading Author

Brendon Chua Author

David Jackson Author

Katherine Kedzierska Author

Related Projects (2)

UNDERSTANDING AND CONTROLLING INFLUENZA

While current influenza vaccines blunt winter epidemics, they must be updated frequently to keep up with virus mutation and they do not prot..

Influenza and viral escape

Introduction of a new influenza strain into human circulation leads to a rapid global spread of the virus (e.g. H1N1-09 pandemic) due to min..

Grants

Awarded by National Health and Medical Research Council

Funding Acknowledgements

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The work was supported by Australian National Health and Medical Research Council (NHMRC) Project Grant to KK (GNT1008854), NHMRC Program Grant to SJT (GNT567122), a CASS Foundation Project Grant (to KK), and US government funds through the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, under contract numbers HHSN266200700005C and HHSN272201400006C (Centers of Excellence for Influenza Research and Surveillance) to PT and ALSAC to PT. KK is a NHMRC Career Development Fellow Level 2 and SJT is an ARC Future Fellow Level 3. The Melbourne WHO Collaborating Centre for Reference and Research on Influenza is supported by the Australian Government Department of Health.